एम्लोडिपिन और ओल्मेसार्टन और एफाविरेंज़, लैमिवुडिन और टेनोफोविर का इंटरैक्शन

• Increased exposure of amlodipine when coadministered with CYP3A inhibitors Olmesartan medoxomil ( 7.2 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS) may lead to increased risk of renal impairment and loss of antihypertensive effect.

CYP3A Inhibitors : Co-administration of amlodipine with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction.

Monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A inhibitors to determine the need for dose adjustment .

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers.

CYP3A Inducers: No information is available on the quantitative effects of CYP3A inducers on amlodipine.

Calcium channel blockers: Diltiazem ↓ diltiazem ↓ desacetyl diltiazem ↓ N-monodesmethyldiltiazem Diltiazem dose adjustments should be guided by clinical response (refer to the full prescribing information for diltiazem).

Others (e.g., felodipine, nicardipine, nifedipine, verapamil) ↓ calcium channel blocker When coadministered with EFV, dosage adjustment of calcium channel blocker may be needed and should be guided by clinical response (refer to the full prescribing information for the calcium channel blocker).